Navigation Links
NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
Date:9/15/2008

PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced successful top-line results from the second phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met the three co-primary efficacy endpoints at week-13 (p<0.001). The study also comfortably met the main secondary endpoint, demonstrating that naproxcinod 750 mg bid was statistically non-inferior to naproxen 500 mg bid on the WOMAC(TM) pain and function subscales at week-13 and 26. Naproxcinod is the first compound in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donator (CINOD) class of anti-inflammatory agents, which NicOx is developing as a drug for the treatment of the signs and symptoms of osteoarthritis.

NicOx' phase 3 clinical program for naproxcinod consists of three pivotal trials (including the previously completed 301 study in osteoarthritis of the knee and the ongoing 303 study in osteoarthritis of the hip, in addition to the 302 study). Overall, the results of the 302 study support naproxcinod's non-detrimental effect on blood pressure and are consistent with those observed in the 301 study, with naproxcinod 750 mg bid showing a numerical reduction in systolic and diastolic blood pressure at week-13 and 26, compared to baseline and naproxen 500 mg bid. Existing non-steroidal anti-inflammatory agents (NSAIDs) such as ibuprofen and naproxen have the tendency to raise blood pressure, which is a side effect of particular concern in the osteoarthritis population.

A post hoc pooled analysis of the blood pressure data from the 301 and 302 studies showed a statistically significant reduction for naproxcinod 750 mg bid, compared to naproxen 500 mg bid, in terms of the mean change from baseline at week-13, of 2.3 mmHg (p=0.004) for systolic blood pressure and 1.1 mmHg (p=0.034) for diastolic blood pressure. In the planning of the phase 3 program, NicOx had fo
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
2. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
3. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
4. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
5. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
6. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
9. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
10. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
11. NicOx Naproxcinod ABPM Data Presented at American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ...  report to their offering. Global Guidewires sector is ... North America accounts for nearly 35% ... claims approximately 25% (2018). Asia-Pacific ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... , CLEVELAND , Feb. 9 DATATRAK International, ... eClinical solutions for the clinical trials industry, today announced that it ... seminar in Tel Aviv, Israel , focusing on eClinical solutions ... will identify and decipher the challenges, costs and obstacles customarily encountered ...
... , Feb. 9 Visage Imaging®, Inc., a wholly ... John Danahy joins as General Manager North America , ... industry, Johns brings a wealth of experience to the Visage team. ... managed the national sales organization and developed new business opportunities in ...
Cached Medicine Technology:DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 2DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 3DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 4Visage Imaging Names John Danahy as General Manager North America, Sales and Services 2
(Date:12/19/2014)... December 19, 2014 This is a ... the global Gliquidone industry with a focus on the ... market status of the Gliquidone manufacturers and is a ... individuals interested in the industry. , Firstly, the report ... definition, applications and manufacturing technology. Then, the report explores ...
(Date:12/19/2014)... 19, 2014 The Hermitage Club ... in Southern Vermont’s Deerfield Valley, announced today that it ... classic rock songs. , Three time Grammy Award ... private concert followed by a trail naming ceremony. Hermitage ... names include: “I’m Alright” the theme song for the ...
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... born to moms who were exposed to high levels of ... of developing autism, a U.S. study suggests. Researchers found ... 1990 and 2002, those exposed to the most air pollution ... who later developed autism. And exposure during the third trimester, ...
(Date:12/19/2014)... through the same U.S. airport gate, one infected passenger ... four-hour time span, illustrating just how easily the virus ... in this report were not prolonged and occurred in ... fact that measles is highly contagious," wrote a team ... the U.S. Centers for Disease Control and Prevention. ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3
... has received FDA Clearance for their DPL™ Therapy System for temporary ... ... 16, 2008 -- LED Technologies, LLC announced today that the U.S. ... the relaxation of muscles and relief of muscle spasms, temporary relief ...
... moving, study finds , , FRIDAY, Nov. 14 (HealthDay News) - ... keep excess pounds at bay, according to a U.S. study. ... time, and shown that for children in densely population cities, ... Our new study of over 3,800 inner-city children revealed that ...
... breast cancer is driving a sub-type of the disease ... American women. , The pathway regulates how cells identify ... called proteasome targeting complexes. The work shows that basal ... making a new type of proteasome targeting complex. The ...
... Innovative approach could give heart attack victims, other patients ... News) -- U.S. government scientists say they have developed ... directly into the body to cool and to protect ... "ice slurry" can be pumped easily into the body ...
... finds nearly two-thirds of Americans believe so, even though ... 14 (HealthDay News) -- A majority of Americans, including many ... are at least partly to blame for their disease, ... nearly 1,500 American adults, researchers found 59 percent of ...
... innovative plan to get new life-saving drugs into the hands ... but can,t afford the massive costs will be unveiled to ... weeks. , "Pharmaceuticals have become an increasingly important part of ... of money spent on them in developed countries like Canada ...
Cached Medicine News:Health News:FDA Clears the DPL (Deep Penetrating Light) Therapy System for Over-the-Counter - Home Use 2Health News:Greener Neighborhoods Mean Slimmer Children 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 3Health News:IV 'Ice Slurry' Quickly Cools Body for Surgeries 2Health News:Lung Cancer Patients Get Blamed for Their Disease 2Health News:Lung Cancer Patients Get Blamed for Their Disease 3Health News:Affordable medicine plan goes global 2Health News:Affordable medicine plan goes global 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: